- Home
- HCA vs GSK Comparison
HCA vs GSK Comparison
Compare HCA & GSK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCA
- GSK
- Stock Information
- Founded
- HCA 1968
- GSK 1715
- Country
- HCA United States
- GSK United Kingdom
- Employees
- HCA N/A
- GSK N/A
- Industry
- HCA Hospital/Nursing Management
- GSK Biotechnology: Pharmaceutical Preparations
- Sector
- HCA Health Care
- GSK Health Care
- Exchange
- HCA Nasdaq
- GSK Nasdaq
- Market Cap
- HCA 79.4B
- GSK 71.7B
- IPO Year
- HCA N/A
- GSK N/A
- Fundamental
- Price
- HCA $335.01
- GSK $35.93
- Analyst Decision
- HCA Buy
- GSK Hold
- Analyst Count
- HCA 17
- GSK 4
- Target Price
- HCA $376.20
- GSK $47.00
- AVG Volume (30 Days)
- HCA 1.7M
- GSK 6.0M
- Earning Date
- HCA 04-25-2025
- GSK 04-30-2025
- Dividend Yield
- HCA 0.86%
- GSK 4.32%
- EPS Growth
- HCA 15.97
- GSK N/A
- EPS
- HCA 22.00
- GSK 0.78
- Revenue
- HCA $70,603,000,000.00
- GSK $39,280,393,592.00
- Revenue This Year
- HCA $6.80
- GSK $7.60
- Revenue Next Year
- HCA $5.16
- GSK $5.24
- P/E Ratio
- HCA $15.23
- GSK $22.27
- Revenue Growth
- HCA 8.67
- GSK 3.46
- 52 Week Low
- HCA $289.98
- GSK $31.72
- 52 Week High
- HCA $417.14
- GSK $45.93
- Technical
- Relative Strength Index (RSI)
- HCA 51.04
- GSK 45.54
- Support Level
- HCA $329.15
- GSK $32.38
- Resistance Level
- HCA $341.39
- GSK $36.16
- Average True Range (ATR)
- HCA 11.80
- GSK 1.16
- MACD
- HCA -1.19
- GSK -0.13
- Stochastic Oscillator
- HCA 47.43
- GSK 52.28
About HCA HCA Healthcare Inc.
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the United States. As of June 2024, the firm owned and operated 188 hospitals, 123 freestanding outpatient surgery centers, and a broad network of physician offices, urgent-care clinics, and freestanding emergency rooms across 20 states and a small foothold in England.
About GSK GSK plc (Each representing two)
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.